Degarelix:一种治疗前列腺癌的新激素

Future Prescriber Pub Date : 2009-02-26 DOI:10.1002/fps.42

Professor Malcolm Mason

{"title":"Degarelix:一种治疗前列腺癌的新激素","authors":"Professor Malcolm Mason","doi":"10.1002/fps.42","DOIUrl":null,"url":null,"abstract":"According to NICE, prostate cancer constitutes about 25% of new diagnoses of malignant cancer in men in England and Wales.1 The largest single area of spending on cancer drugs is on hormonal therapy, accounting for about 40% of the £292 million total. This article focuses on a novel hormonal treatment for prostate cancer, degarelix. Copyright © 2009 John Wiley & Sons, Ltd.","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"10 1","pages":"11-15"},"PeriodicalIF":0.0000,"publicationDate":"2009-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.42","citationCount":"3","resultStr":"{\"title\":\"Degarelix: a new hormonal treatment for prostate cancer\",\"authors\":\"Professor Malcolm Mason\",\"doi\":\"10.1002/fps.42\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"According to NICE, prostate cancer constitutes about 25% of new diagnoses of malignant cancer in men in England and Wales.1 The largest single area of spending on cancer drugs is on hormonal therapy, accounting for about 40% of the £292 million total. This article focuses on a novel hormonal treatment for prostate cancer, degarelix. Copyright © 2009 John Wiley & Sons, Ltd.\",\"PeriodicalId\":100566,\"journal\":{\"name\":\"Future Prescriber\",\"volume\":\"10 1\",\"pages\":\"11-15\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2009-02-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1002/fps.42\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future Prescriber\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/fps.42\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/fps.42","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 3

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Degarelix: a new hormonal treatment for prostate cancer

According to NICE, prostate cancer constitutes about 25% of new diagnoses of malignant cancer in men in England and Wales.¹ The largest single area of spending on cancer drugs is on hormonal therapy, accounting for about 40% of the £292 million total. This article focuses on a novel hormonal treatment for prostate cancer, degarelix. Copyright © 2009 John Wiley & Sons, Ltd.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Future Prescriber

自引率

0.00%

发文量